Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options

Péter Bencsik1,2 | Kamilla Gömöri1,2 | Tamara Szabados1,2 | Péter Sántha3 | Zsuzsanna Helyes4,5 | Gábor Jancsó3 | Péter Ferdinandy2,6 | Anikó Görbe1,2,6

1 Cardiovascular Research Group, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Szeged, Hungary
2 Pharmahungary Group, Szeged, Hungary
3 Department of Physiology, Faculty of Medicine, University of Szeged, Szeged, Hungary
4 Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary
5 Molecular Pharmacology Research Group, Centre for Neuroscience, János Szentágothai Research Centre, University of Pécs, Pécs, Hungary
6 Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary

Correspondence
Peter Bencsik, MD, PhD, Cardiovascular Research Group, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Dom ter 12, H-6720 Szeged, Hungary.
Email: bencsik.peter@med.u-szeged.hu

Funding information
National Research, Development and Innovation Office of Hungary, Grant/Award Numbers: NVKP 16-1-2016-0017, GINOP-2.3.2-15-2016-00040

During the last decades, mortality from acute myocardial infarction has been dramatically reduced. However, the incidence of post-infarction heart failure is still increasing. Cardioprotection by ischaemic conditioning had been discovered more than three decades ago. Its clinical translation, however, is still an unmet need. This is mainly due to the disrupted cardioprotective signalling pathways in the presence of different cardiovascular risk factors, co-morbidities and the medication being taken. Sensory neuropathy is one of the co-morbidities that has been shown to interfere with cardioprotection. In the present review, we summarize the diverse aetiology of sensory neuropathies and the mechanisms by which these neuropathies may interfere with ischaemic heart disease and cardioprotective signalling. Finally, we suggest future therapeutic options targeting both ischaemic heart and sensory neuropathy simultaneously.

Abbreviations: AMI, acute myocardial infarction; CAN, cardiovascular autonomic neuropathy; CMT, Charcot–Marie–Tooth disease; FD, familial dysautonomia; HFrEF, heart failure with preserved ejection fraction; HSANs, hereditary sensory and autonomic neuropathies; IKBKAP, in B-cells kinase complex-associated protein; PDE5, PDE type 5; RA, rheumatoid arthritis; RTX, resiniferatoxin; SERCA2a, sarco-endoplasmic reticulum Ca2+-ATPase type 2a; SLE, systemic lupus erythematosus; SP, substance P; SST, somatostatin; STZ, streptozotocin; TH, tyrosine-hydroxylase; TRP, transient receptor potential; TRPA1, transient receptor potential ankyrin 1; TRPV1, transient receptor potential vanilloid type 1.
INTRODUCTION—CARDIOPROTECTION AND SENSORY NERVES IN THE HEART

The acute care of myocardial infarction has been dramatically improved by the introduction of percutaneous coronary intervention and stenting thereby decreasing its early mortality. However, the incidence of chronic postinfarction heart failure is rising faster than previously expected (Lam, Donal, Kraigher-Krainer, & Vasan, 2011). Cardioprotective interventions such as local and remote ischaemic and pharmacological pre-conditioning, post-conditioning, and per-conditioning have been discovered and extensively studied in the last three decades (Ferdinandy, Hausenloy, Heusch, Baxter, & Schulz, 2014). However, their clinical translation has been failed so far, most probably due to several confounding factors including co-morbidities, co-medications and variable genetic background (see for a recent extensive review Hausenloy et al., 2017). Among cardiovascular co-morbidity states such as hyperlipidaemia, diabetes mellitus and confounders such as aging or sex differences (see for reviews Ferdinandy et al., 2014; Ferdinandy, Szilvassy, & Baxter, 1998), sensory neuropathy has also been recognized as a confounding factor. Nevertheless, only a small amount of preclinical and clinical data are available on the influence of sensory neuropathy to ischaemic heart disease and cardioprotection (Ieda & Fukuda, 2009).

The innervation of the heart is composed of intricate feedback loops of autonomic nervous system consisting of intrinsic cardiac ganglia, extracardiac intrathoracic ganglia, the spinal cord and areas of the CNS (Ardell et al., 2016). The effector machinery involves autonomic neurons of the sympathetic and parasympathetic nervous systems, as well as non-adrenergic–non-cholinergic (NANC) sensory nerves activated by hypoxia, ROS and increased concentrations of H⁺ and K⁺, leading to the release of neuropeptide transmitters (Franco-Cereceda & Lundberg, 1988; see Figure 1). Cardiac sensory nerves can be localized separately having their own separate afferent soma inside intrinsic cardiac ganglionated plexi, but most of them are coupled to autonomic nerves including the parasympathetic vagal and sympathetic efferents (Ardell et al., 2016). In the clinical settings, pathologies impairing sensory nerves frequently also affect autonomic nerves, thereby combining the symptoms derived from both sensory and/or autonomic neuropathies, which lead to complex clinical presentation of the symptoms. Even in cases of primary, hereditary neuropathies (see below), neural injury shows a mixture of sensory and autonomic dysfunctions. Only preclinical models (e.g. capsaicin or resiniferatoxin (RTX)-induced desensitization) are appropriate to clearly describe the cardiac effects of selective sensory neuropathy. Sensory neuropathy may affect all

FIGURE 1 Sensory innervation of the heart. We focused on cardiac sensory nerves, but there are several other types of cardiac nerves and neurons (see in detail in the text of Section 2). Cardiac sensory fibres are coupled to both sympathetic and parasympathetic (vagus) nerves and can be separated from the autonomic nervous system. The capsaicin-sensitive sensory nerve terminals are activated and sensitized by a variety of mediators produced by ischaemia, inflammation and tissue damage, and mediate sensory input pain and reflexes (classical afferent function). β1R, β1-adrenoceptor; DRG, dorsal root ganglion; PGs, prostaglandins; M2R, M2 receptor; TRPA1, transient receptor potential ankyrin 1; TRPV1, transient receptor potential vanilloid-1
types of sensory neurons involved in myocardial regulation and therefore, in most pathologies affecting the complex cardiac sensory machinery, it is hard to distinguish between the localization of the lesion/s and the degree of neural damage.

Although sensory and autonomic neuropathies are important common contributors to the development of ischaemic heart disease, they are still not the focus of cardiovascular research. However, better understanding of these mechanisms may help to develop effective cardioprotective therapies. In this review, we collected the available data to summarize the diverse causes of sensory neuropathy and its contribution to cardiac pathology. We systematically evaluate preclinical models used to investigate the cardiac consequences of sensory neuropathy, as well as clinical data on concomitant occurrence of sensory neuropathies and cardiac pathologies. Furthermore, we summarize the mechanisms and effects of sensory neuropathy on myocardial ischaemia and cardioprotection. Finally, we highlight the therapeutic perspectives to achieve cardioprotection in the presence of sensory neuropathy.

2 | PHYSIOLOGICAL ROLE OF CARDIAC SENSORY NERVES

The complexity of the functional role of sensory nerves innervating the heart has only recently been recognized. Classical studies have revealed the anatomy and functional significance of cardiac sensory nerves in the mechanisms of fundamental reflexes regulating heart function (Dawes & Comroe, 1954). Cardiac innervation includes a complex multiple-levelled regulatory system consisting of feedback and feed-forward neuronal circuits. Intrinsic cardiac ganglion plexus contains sympathetic and parasympathetic postganglionic efferent neurons, local circuit and afferent neurons, while extracardiac intrathoracic ganglia possess afferent and local circuit neuron as well as sympathetic postganglionic efferents. Neurons in both circuits form regulatory loops with higher centres (e.g. spinal cord, medulla oblongata and hypothalamus) under cortical neuronal control (Ardell et al., 2016). Cardiac afferents are coupled to both sympathetic and parasympathetic (vagus) efferent nerves and can also be separated from the autonomic nervous system (Figure 1). Cardiac afferent nerves, which can be excited by capsaicin, were first identified in investigations into the mechanisms of action of cardiorespiratory chemoreflexes. These studies showed that a substantial population of chemosensitive afferent nerves that convey these reflexes are activated by capsaicin (Porszasz, Gyorgy, & Porszasz-Gibiszner, 1955). The characteristic cardiorespiratory chemoreflex evoked by capsaicin consisting of bradycardia, hypotension and apnoea could be inhibited by prior perineural treatment of the cervical vagal nerves with capsaicin, resulting in the selective interference of the function of capsaicin- but not phenylbiguanide-sensitive C-fibres (Jancsó & Such, 1983). Chemosensitive afferents sense cardiac pain and mediate the cardiogenic sympathetic reflex (Pan & Chen, 2004).

Capsaicin is the pungent component of peppers that is able to selectively activate and/or disrupt an important subpopulation of sensory neurons, thinly myelinated Aδ and/or unmyelinated C fibres (Jancsó, 1968). Systemic administration of high-dose capsaicin disrupts these primary sensory neurons in a rather more complex way. In newborn animals, systemic administration of high-doses of capsaicin results in a selective loss of small, type B nociceptive primary sensory neurons (Jancso, Kiraly, & Jancso-Gabor, 1977), but in adults, it produces long-term desensitization and functional impairment of these neurons. Quantitative electron microscopic examination revealed a significant and selective loss of about 40% of unmyelinated afferent axons in peripheral sensory nerves (Jancso, Kiraly, Joo, Such, & Nagy, 1985) and up to 94% in spinal dorsal roots (Nagy, Iversen, Goedert, Chapman, & Hunt, 1983). Importantly, autonomic nerve fibres are not affected by capsaicin treatment (Jancsó, Such, Király, Nagy, & Bujdosó, 1985). In contrast to the comparatively moderate loss of C sensory fibre number, profound reduction was detected in the levels of neuropeptide transmitters specific to these nociceptive primary sensory neurons (Gamse, Lackner, Gamse, & Leeman, 1981; Jancso & Knyihar, 1975).

There is ample evidence that the effects of capsaicin are being mediated through the activation of the transient receptor potential vanilloid type 1 receptor (TRPV1) also known as the vanilloid receptor 1 or the capsaicin receptor (Caterina et al., 1997) expressed in chemosensitive primary sensory neurons. TRPV1 receptor physiologically can be activated and/or sensitized by several stimuli, such as H+, K+, bradykinin, ROS and prostaglandins (Nagy, Santha, Jancso, & Urban, 2004; Randhawa & Jaggi, 2015; Figures 1 and 2). Another TRP receptor, transient receptor potential ankyrin 1 (TRPA1) is expressed and co-localized with TRPV1 receptors in the cardiac muscle (Andreï, Sinharoy, Bratz, & Damron, 2016). TRPA1 is also present on vascular smooth muscle cells and sensory nerves in the heart, which are also activated by ROS, Ca2+ and prostaglandins (Wang, Ye, et al., 2019; Figures 1 and 2). Anatomical and functional evidence indicate that capsaicin-sensitive primary afferent neurons of both spinal (thoracic dorsal root ganglia) and vagal (nodose ganglion) origins innervate the heart (Ferdinand et al., 1997; Jancso & Such, 1983; Pan & Chen, 2004).

A significant proportion of chemosensitive afferents expressing the TRPV1 receptor are peptidergic, which are involved in more functions than just sensory input such as pain and reflex regulation of the cardiorespiratory system. Sensory neuropeptides are released from these fibres in response to activation not only experimentally by capsaicin and exogenous vanilloid, but also by a broad range of inflammatory stimuli and tissue irritants which exert important effector functions on the heart (Jancsó, 1968; Jancso, Kiraly, Such, Joo, & Nagy, 1987). CGRP, substance P (SP) and pituitary adenylate cyclase-activating polypeptide (PACAP-38) induce vasodilatation, plasma protein activation and mainly immune and inflammatory cell activation in the innervated area, collectively called neurogenic inflammation (Figure 2; Holzer, 1988). Meanwhile besides the pro-inflammatory peptides, inhibitory mediators, such as somatostatin, galanin and opioid peptides are also released from the same capsaicin-sensitive sensory nerves in response to activation, which have anti-oedema, anti-inflammatory, analgesic and cytoprotective actions when entering the
systemic circulation, even at distant parts of the body (Holzer, 1988; Jancko et al., 1987; Szolcsanyi, Pinter, Helyes, & Petho, 2011). Pituitary adenylate cyclase-activating polypeptide (Harmar et al., 2012) and CGRP (Li & Peng, 2002) are interesting as they are multifunctional peptides. They have strong vasodilating actions contributing to the vascular components of the inflammatory response, but also have a potent inhibitor action on the cellular inflammatory mechanisms and direct cytoprotective actions on the cardiomyocytes (Figure 2).

### 3 | MOLECULAR CHANGES IN THE MYOCARDIUM IN THE PRESENCE OF CAPSAICIN-INDUCED SENSORY NEUROPATHY

A limited number of preclinical papers are available in the literature which discuss the effect of sensory neuropathy on cardiac cell signaling. Most of the data are restricted to the sensory neuropathy evoked by systemic capsaicin treatment-induced sensory desensitization. Therefore, in the following section, we will present data from papers using preclinical model of capsaicin-induced sensory neuropathy.

More than a decade ago, Zvara et al. showed cardiac functional alterations and gene expression changes in rat hearts 7 days after the induction of sensory neuropathy by systemic capsaicin treatment, using DNA microarray technique. Capsaicin-induced sensory neuropathy resulted in cardiac dysfunction characterized by elevation of left ventricular end-diastolic pressure which led to significant up-regulation of 47 and significant down-regulation of 33 genes out of 6400 genes available on the microarray. Sensory neuropathy has been shown to influence a variety of neuronal and non-neuronal genes in the heart including vanilloid receptor-1 (TRPV1), GABA receptor rho-3 subunit, cytochrome P450 subfamily 2A, polypeptide 1 (CYP2A1), 5-HT3B receptor, NK2 receptor, matrix metalloproteinase-13, farnesyl-transferase, APOB apolipoprotein, leptin and endothelial NOS (Zvara et al., 2006).

Bencsik et al. found that sensory neuropathy (chemo-denervation) induced by 7 days of capsaicin treatment decreased the cardiac NO availability via decreased activity of Ca2+-dependent NOS isoforms (endothelial NOS and nNOS) and increased SOD activity thereby leading to decreased basal ONOO− formation and a reduction of S-nitrosylation of sarco-endoplasmic reticulum Ca-ATPase type 2a (SERCA2a), which caused impaired myocardial relaxation in the rat.
heart. The gene expression pattern of the three different isoforms of NOS in the heart were also examined by real-time quantitative PCR. Endothelial NOS (eNOS) was significantly down-regulated due to capsaicin-desensitization. However, the expression of neuronal and inducible NOS isoforms was unaffected (Bencsik et al., 2008).

A recent animal study of capsaicin-induced sensory neuropathy revealed microRNA changes in the rat heart after 7 days of treatment (Bencsik et al., 2019). Echocardiographic data showed a moderate diastolic dysfunction in sensory neuropathy group and several microRNA showed altered expression. Out of 711 miRNAs represented on the miRNA microarray, the expression of 257 miRNAs was detectable, from which miR-344b, miR-466b miR-98, let-7a, miR-1, miR-206 and miR-34b showed down-regulation and miR-181a was up-regulated due to sensory neuropathy. The altered miRNAs were selected for an unbiased bioinformatic miRNA-target network analysis, which predicted several target genes including insulin-like growth factor 1, solute carrier family 2, facilitated glucose transporter member 12, eukaryotic translation initiation factor 4e and unc-51 like autophagy activating kinase 2, which were validated as potentially contributing factors to cardiac diastolic dysfunction induced by sensory neuropathy (Bencsik et al., 2019).

4 | THE EFFECTS OF SENSORY NEUROPATHY ON MYOCARDIAL ISCHAEMIA/REPERFUSION INJURY AND INFARCTION

The number of available published papers in this special cardiovascular field is quite limited. The first report for the effects of sensory neuropathy during the course of myocardial infarction was published by Nesto and colleagues. They showed that diabetes-induced sensory neuropathy may contribute to asymptomatic myocardial infarction, probably due to lack of pain sensation as a result of injured sensory nerves (Nesto & Phillips, 1986). Subsequently, several publications confirmed the potential influence of diabetes-induced sensory neuropathy in asymptomatic or silent ischaemia by enrolling a high number of acute myocardial infarction (AMI) or coronary artery disease patients (Elliott et al., 2019). The first preclinical characterization of experimental acute myocardial ischaemia/reperfusion injury ex vivo after in vivo capsaicin-induced sensory neuropathy was published in 1997 by Ferdinandy et al. The authors did not observe significant changes in ischaemia/reperfusion injury but a loss of pre-conditioning-induced cardioprotection (see next chapter). In another in vivo study of myocardial infarction in the presence of capsaicin-sensitive sensory nerve degeneration (Zhang, Guo, Wang, & Wu, 2012), the authors used a rat model of capsaicin-sensitive sensory desensitization induced by single subcutaneous capsaicin injection within the first 48 hr after birth. Selective desensitization of capsaicin-sensitive nerves was validated by a significant deterioration in tail flick test in the capsaicin-treated group of rats at12 weeks of age before conducting permanent coronary ligation. They found that infarct size was significantly increased by sensory desensitization 6 hr after the induction of coronary ligation. Furthermore, their finding was further supported by the increased troponin I level and enhanced apoptosis shown by elevated caspase-3 levels in the desensitized group (Zhang et al., 2012). Earlier studies using systemic capsaicin pretreatment indicated that chemosensitive afferent nerves confer cardioprotective effects since prior to chemo-denervation by capsaicin impaired post-ischaemic recovery was shown in isolated rat hearts (Ustinova, Bergren, & Schultz, 1995) and an increase in the size of the myocardial infarction was found in an in vivo porcine model of acute myocardial infarction (AMI; Kallner, 1998). However, in the above-mentioned studies, the presence of sensory neuropathy was not verified. The cardioprotective effect conferred by capsaicin-sensitive afferents appeared to be mediated through activation of the TRPV1 receptor which in turn induces release of substance P and CGRP from sensory nerves. The role of the TRPV1 receptor in cardioprotection was supported by the finding that post-ischaemic recovery was impaired in TRPV1 knockout mice (Wang & Wang, 2005). Furthermore, administration of an endogenous vanilloid, N-oleoyl dopamine, protected the ex vivo isolated mouse heart from ischaemia–reperfusion injury by activating the TRPV1 receptor (Zhong & Wang, 2008).

In contrast, most recently, selective chemical ablation of TRPV1 positive neurons in the stellate ganglion by intra-ganglionic injection of resiniferatoxin has been shown to decrease the incidence of severe ventricular arrhythmias in dogs subjected to 60-min coronary ligation (Zhou et al., 2019). This study suggests a pro-arrhythmic role of TRPV1 positive neurons in the sympathetic nervous system innervating the heart.

5 | CARDIOPROTECTION IN THE PRESENCE OF SENSORY NEUROPATHY

Since neuropathy manifests in the clinical scenario in a complex manner, it is hard to separately characterize the sensory neuropathy components of a pathology. Human data are mostly related to different polyneuropathy conditions or cardiac autonomic neuropathy. However, the results of some animal models specifically mimicking sensory neuropathy revealed a role for sensory nerves in several mechanisms of cardioprotection. An excellent review was recently published about the function of intact cardiac innervation in cardioprotection by remote ischaemic conditioning (Hausenloy et al., 2019), focusing on diabetic neuropathy in remote conditioning. Therefore, in the present review, we have focused on myocardial ischaemia/reperfusion injury and cardioprotection in the presence of a wide range of co-morbidities, where the deterioration of sensory neural system has been shown to be involved in these pathologies. Cardioprotection (local and remote) can be classified at three different levels which are stimulus, transfer and target levels (Kleinbongard, Skyschally, & Heusch, 2017). Both sensory and autonomic nerves might be involved in all of these three levels. The complex actions of sensory and autonomic nerves involving higher CNS regions, such as the spinal cord or brainstem, have been reviewed in detail (Kleinbongard et al., 2017). However, the current knowledge on the specific contribution of...
sensory nerves to cardioprotection is not sufficient precise to classify their diverse actions at these three levels of cardioprotection.

More than two decades ago, we showed that systemic desensitization of the capsaicin-sensitive afferents by high-dose capsaicin pre-treatment in rats abolished the protective effect of pre-conditioning evoked by rapid ventricular pacing in isolated hearts with coronary occlusion and reperfusion (Ferdinandy et al., 1997). Several publications reported that ischaemic pre-conditioning-induced cardioprotection is attenuated in animal models of Type 2 diabetes, when diabetic neuropathy is present (extensively reviewed elsewhere, Whittington, Babu, Mocanu, Yellon, & Hausenloy, 2012). Furthermore, the cardioprotective effect of patients’ serum taken after cycles of BP cuff inflation/deflation of the arm was only detected in cases of healthy subjects and diabetics without neuropathic complications, when these serum samples were applied to the isolated rabbit hearts with ischaemia–reperfusion injury (Jensen, Stottrup, Kristiansen, & Botker, 2012). The critical role of TRPV1 receptors in ischaemic pre-conditioning was also demonstrated in experiments showing that deletion of the TRPV1 gene impaired pre-conditioning-induced cardioprotection, the protection being mediated by the release of substance P and CGRP from sensory nerves (Zhong & Wang, 2008). The pivotal role of TRPV1 receptor activation is strongly supported by the results that TRPV1 knockout animals show impaired post-ischaemic recovery (Wang & Wang, 2005). This combined experimental data unequivocally indicates that activation of cardiac capsaicin-sensitive afferents confer potent cardioprotective effect on the myocardium, through the release of the above neuropeptides. Furthermore, nerve growth factor has been shown to be critical for up-regulation of TRPV1 receptors in primary sensory neurons from adult rats (Winter, Forbes, Sternberg, & Lindsay, 1988), in particular those containing CGRP. The role of TRPV1 receptor in cardioprotection was supported by the finding that reperfusion injury of diabetic mice hearts was attenuated after nerve growth factor administration up-regulated TRPV1 receptor expression (Zheng et al., 2015). Although these results clearly demonstrate the critical role of capsaicin-sensitive afferent nerves and their TRPV1 receptors in cardioprotection against ischaemic injury, a potential role of TRPV1 receptors expressed by rat cardiomyocytes (Qi et al., 2015; Zvara et al., 2006) has not been considered. Data about the involvement of TRPA1 channels in cardioprotection are controversial. Activation of TRPA1 by optovin led to enhanced survival rate of cardiac myocytes subjected to simulated ischaemia and reperfusion (Lu, Pipani, McAllister, Hurt, & Gross, 2016). However, in vivo coronary occlusion/reperfusion in TRPA1 knockout mice resulted in a reduction of myocardial infarct size (Conklin et al., 2019).

Both substance P and CGRP have been shown to participate in sensory nerve-mediated cardioprotection. Myocardial ischaemia is associated with a decrease in the cardiac level of substance P and in turn, administration of substance P reduced ischaemic myocardial damage in Langendorff-perfused hearts of rats subjected to systemic capsaicin pretreatment (Ustinova et al., 1995). Experimental evidence indicates that CGRP released from capsaicin-sensitive cardiac afferents also induces cardioprotection against ischaemic myocardial damage in pig and rat acute myocardial injury models (Kallner, 1998; Li, Xiao, Peng, & Deng, 1996). The role of CGRP and NO in the pacing-induced and capsaicin-sensitive nerve-mediated cardioprotection has been previously demonstrated (Ferdinandy, 2009; Ferdinandy et al., 1997). Cardioprotective effect of remote pre-conditioning induced by direct stimulation of sensory nerves is mediated by the release of cardioprotective humoral factors, including sensory neuropeptides and NO. This humoral response was abolished by topical DMSO treatment damaging the sensory nerves and also by intra-arterial NO-donor treatment applied prior to stimulating the sensory nerves with topical capsaicin treatment in an in vivo remote ischaemia/reperfusion rabbit model (Redington et al., 2012).

Further evidence for the neural component of remote ischaemic pre-conditioning is that hexamethonium, a selective ganglionic blocker, can abolish the cardioprotective protective effects of short mesenteric artery occlusion-triggered adenosine release in an in vivo rat model of acute myocardial infarction (Liem, Verdouw, Ploeg, Kazim, & Duncker, 2002). However, the latter study has not investigated the role of sensory nerves in its remote ischaemic pre-conditioning model. Recently, it has been reported that somas of sensory neurons may release exosomes (a type of extracellular vesicles) containing micro-RNAs and other factors by which they can regulate cell–cell communication (Simeoli et al., 2017).

6 | CO-MORBIDITIES SIMULTANEOUSLY AFFECTING THE SENSORY NERVES AND THE HEART

In this section, we describe several disease states leading to sensory neuropathy and ischaemic or other cardiac pathologies simultaneously. We summarize the main features of each disease, provide human data in relation to sensory neuropathy and cardiac symptoms and finally, show preclinical research models for sensory neuropathy of different aetiologies (see also Table 1). The available animal models are mainly rodent models with several limitations, but they can be suitable to investigate how sensory nerves influence the ischaemic myocardium. Large animal models for neuropathies are scarce in the literature, but some canine models for primary sensory neuropathies have recently been developed (Correard et al., 2019).

6.1 | Primary neuropathies: Hereditary disorders

There are several types of genetic disorders, which lead to sensory neuropathy and may be related to cardiovascular symptoms.

Charcot–Marie–Tooth (CMT) disease is the most frequently occurring hereditary sensory peripheral polyneuropathy caused by mutations affecting mainly myelinated Schwann cells (CMT1) or it is characterized by axonal degeneration (CMT2; Timmerman, Strickland, & Zuchner, 2014). In the extensive literature on this disease only a few case reports refer cardiac effects. In a recent paper, regarding CMT disease, a novel cardiomyopathy condition, non-
| Pathologies affecting cardiac sensory neurons | Disease                                                                 | Clinical cardiac symptoms                                                                 | References                                                                                       | Available animal models of the disease | References                      |
|----------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------|----------------------------------|
| Primary neuropathies                         | Charcot–Marie–Tooth disease                                             | Noncompaction cardiomyopathy, increased incidence of arrhythmias, and embolic complications | Blawansy et al., 2015                                                                          | CMT1: PMP22 overexpressed transgenic rodents                                       | Huxley et al., 1998 Sereda et al., 1996 |
|                                               | Familial dysautonomia (HSAN Type III)                                   | Cardiovascular instability, postural hypotension, episodic hypertension, QT variability, and ECG abnormalities | Goldstein et al., 2008 Seredanazeleh et al., 2008                                              | Ikbbap conditional-knockout mouse lines, Ikbbap<sup>−/−</sup> and Ikbbap<sup>−/−</sup> | Dietrich et al., 2012 Ohlen et al., 2017 |
|                                               | Hereditary transthyretin-mediated amyloidosis                           | Refractory cardiomyopathy, orthostatic hypotension, and arrhythmias                        | Adams et al., 2019                                                                             | Mouse expressing human transthyretin V30M in a heat shock transcription factor 1 null background | Santos et al., 2010               |
|                                               | Friedreich’s ataxia                                                    | Hypertrophic cardiomyopathy, atrial fibrillation, and ventricular tachycardia               | Peverill et al., 2018                                                                          | Conditional frataxin knockout mouse                                                    | Puccio et al., 2001               |
| Secondary neuropathies                       | Diabetes mellitus (Type 1)                                              | Diastolic cardiomyopathy and heart failure with reduced ejection fraction                  | Voulgari et al., 2010                                                                          | Single high dose of STZ or multiple moderate dose of STZ                               | Bakovic et al., 2018 Kellogg, Converso, Wiggin, Stevens, and Pop-Busui, 2009 Grise et al., 2016 Xuan et al., 2015 |
|                                              | Diabetes mellitus (Type 2)                                              | Increased heart rate                                                                      | Aune et al., 2017                                                                              | High-fat diet for 14 weeks and single dose of STZ (30 mg·kg<sup>−1</sup>)              | Li et al., 2017                   |
|                                              | Pre-diabetes                                                           | N/A                                                                                       | N/A                                                                                             | Single low-dose of STZ (20 mg·kg<sup>−1</sup>) and high fat diet                        | Koncsos et al., 2016               |
|                                              | Alcoholism                                                              | No characteristic cardiovascular involvement                                              | Koike et al., 2003                                                                             | Mouse model of chronic plus binge alcohol feeding-induced ethanol intoxication         | Matyas et al., 2016               |

(Continues)
| Pathologies affecting cardiac sensory neurons | Disease | Clinical cardiac symptoms | References | Available animal models of the disease | References |
|---------------------------------------------|---------|---------------------------|------------|--------------------------------------|------------|
| Autoimmune                                  | Systemic lupus erythematosus | Left ventricular systolic and diastolic dysfunction | Chen et al., 2016 | N/A | N/A |
|                                             | Rheumatoid arthritis | Conduction disturbances and arrhythmias | Buleu et al., 2019; Seferovic et al., 2006 | TNF-α-transgenic mouse, K/bxN mouse, Collagen-induced arthritis/Collagen-antibody-induced arthritis in rats and mice, Zymosan-induced arthritis in rat, and methylated BSA mouse model | Asquith, Miller, McInnes, and Liew, 2009; Choudhary et al., 2018 |
| Sjögren's syndrome                          |          | Lower heart rate and BP variability | Kovacs et al., 2004 | Autoimmune regulator gene deficient (Aire<sup>−/−</sup>) mice | Chen et al., 2017 |
| Toxic                                       | Paclitaxel, Vincristine, and Adriamycin | Degenerative morphological alterations in cutaneous C-fibre | Boyette-Davis, Xin, Zhang, and Dougherty, 2011; Dux et al., 1999; Siau et al., 2006 | N/A | N/A |
|                                             | Statins  | N/A                       | N/A | N/A | N/A |
|                                             | Antibiotics/antiviral agents | N/A                       | N/A | N/A | N/A |
|                                             | Industrial/agricultural toxins | N/A                       | N/A | N/A | N/A |
| Other                                       | Vitamin deficiency | Atrial fibrillation and sinus tachycardia | Puntambekar et al., 2009 | N/A | N/A |
|                                             | Hypothyroidism | N/A                       | N/A | N/A | N/A |
|                                             | Viral infections (HIV, Zika, and hepatitis C) | N/A                       | N/A | N/A | N/A |
|                                             | Guillain–Barré sy. | Arrhythmias               | Vucic, Kiernan, and Cornblath, 2009 | N/A | N/A |

Note. N/A indicates no available data in the literature.
compaction cardiomyopathy (or ventricular hypertrabeculation), was described (Eltawansy, Bakos, & Checoton, 2015), which is accompanied with high incidence of arrhythmias and embolic complications. Given the numerous mutations and genes associated with CMT, there are several animal models under development. One of them the CMT1A, which represents 70–80% of all CMT1 cases, is caused by a duplication in peripheral myelin protein 22 (PMP22) gene (Inoue et al., 2001). However, cardiac involvements have not been investigated in these models yet.

Other, less common hereditary sensory and autonomic neuropathies (HSANs) are classified into six major types (I–VI) and several further subtypes (Lynch-Godri, De Repentigny, Gagnon, Trung, & Kothary, 2018). Solid evidence of cardiac involvement in these diseases is lacking with one exception, familial dysautonomia (FD, HSAN III). This is a rare neurological disorder caused by a splice mutation in the inhibitor of κ light polypeptide gene enhancer in B-cells kinase complex-associated protein (IKBKAP) gene. Cardiovascular instability is the most striking feature of FD, which is characterized by postural hypotension and episodic hypertension, as well as tachycardia and decreased cardiac sympathetic innervation (Goldstein, Eldadah, Sharabi, & Axelrod, 2008). FD patients have an increased index of QT variability and decreased heart rate variability which is predictive of mortality. Further, multiple conventional and advanced electrocardiographic abnormalities suggest structural heart disease. Modelling of FD disease (HSAN III) in mouse has been carried out by several research groups. The development of a suitable mouse model was challenging due to the differences in man and mouse gene splicing and the impact of the disease-causing T to C transition (Rubin & Anderson, 2017). However, during the development of these models, many promising therapeutic strategies and drug candidates have been identified (Yoshida et al., 2015). First attempts to generate a humanized FD mouse using bacterial artificial chromosome to deliver the full human IKBKAP gene containing the mutation (IVS20 + T → C) into the mouse genome were unsuccessful, because the created mouse model did not manifest any FD symptoms and was phenotypically normal (Hims et al., 2007). Using knockout approach was also ineffective, because the complete deletion of mouse Ikbkap results in early embryonic lethality (Chen et al., 2009). Dietrich et al. created two lines of mice carrying a conditional inactivation Ikbkap allele, IkbkapFlox/Flox and IkbkapFlox/Flox. Both lines of mice manifested features of FD, including severe reduction in nociceptive (trkA/CRGP positive) neurons at late gestation, small stature, ataxic gait, loss of fungiform papillae, kyphosis or kyphoscoliosis (Dietrich, Alli, Shanmugasundaram, & Dragatsis, 2012). In the FD mouse models, in dorsal root ganglia mitochondria were depolarized and fragmented and ROS levels were significantly increased, which could validate the presence of neuropathy. Mitochondrial dysfunction is a major factor mediating the death of Ikbkap+/− neurons (Ohlen, Russell, Brownstein, & Lefcort, 2017). In the absence of Ikbkap, cardiac innervation is reduced, but other characteristic cardiac symptoms, which were observed in humans have not been investigated in these animal models.

Hereditary transthyretin amyloidosis (hATTR) due to the deposition of insoluble amyloid fibrils leads to sensory and autonomic neuropathies with simultaneous cardiac complications characterized by refractory cardiomyopathy, which develops due to left ventricular amyloid deposits (Adams, Koike, Slama, & Coelho, 2019). Over 130 mutations may cause hATTR that manifest as combined cardiac and neurologic symptoms. In a most recent retrospective clinical study (Lai et al., 2019), heart failure was found to be the major cause of death in hATTR patients. The authors revealed that the most sensitive prognostic marker for cardiac involvement were global longitudinal strain and mitral valve E/A ratio during echocardiographic analysis. Similarly, to hATTR, there are other types of amyloid deposits, for example gelosin amyloidosis (also known as familial amyloidosis Finnish type), which may simultaneously affect the heart and peripheral nervous system, thereby leading to ventricular arrhythmias or atrio-ventricular blocks. However, these consequences derive from multi-organ amyloid accumulation rather than directly from amyloid-induced damage of the autonomic or sensory nerves (Lehmonen, Kaasalainen, Atula, Mustonen, & Holmstrom, 2019). The attempt to create a successful animal model for hATTR started around 30 years ago (Shimada et al., 1989) and even the ideal model that replicates all human characteristics of the disease is still has not been obtained. In 2010, Santos Fernandes, and Saraiva created a mouse model expressing human transthyretin V30M mutation in a heat shock transcription factor 1 null background, which has been used several times. Santos et al. validated the chronic neurodegeneration in dorsal root ganglia and sciatic nerves, but not early pain symptoms of hATTR, and there was no data on cardiac involvement.

Friedreich’s ataxia (FRDA) is a progressive neurodegenerative disease affecting mainly sensory neurons and nerves of the spinal cord and thereby leads to severe ataxia, nystagmus and other cerebellar symptoms. FRDA caused by an autosomal recessive mutation, which leads to a GAA repeat expansion in intron 1 in the gene of the mitochondrial protein frataxin (Durr et al., 1996). FRDA also involves cardiac disturbances such as increased LV wall thickness, reduced chamber size and finally hypertrophic cardiomyopathy leading to heart failure with preserved ejection fraction (HFpEF; Peverill, Donelan, Corben, & Delatycki, 2018). Impaired myocardial perfusion in an FRDA patient was described to be the result of microvascular abnormality without epicardial coronary artery disease (Raman, Dickerson, & Al-Dahhak, 2008). The occurrence of atrial fibrillation and ventricular tachyarrhythmias is also common, which eventually increases cardiac mortality (Zipse & Aleong, 2016). Association between acute myocardial infarction and FRDA disease was found only in two case reports (Sharma, Kiyokawa, Kim, Lee, & Kasuya, 2002). In 2001, Puccio et al. were the first to create mutant mice through conditional gene targeting (frataxin-deficient line) to evaluate treatment strategies for FRDA. When frataxin gene is ablated in brain (neural tissues) and heart, the mice demonstrate a severe disorganization of cardiomyocytes, dilated cardiomyopathy, very short life span, ataxia and loss of proprioception in behavioural studies, such as the rotarod.

Fabry or Anderson–Fabry disease is an X-chromosome-linked hereditary lipid storage disease caused by various mutations of the human GLA gene resulting in a decreased expression and activity of the lysosomal α-galactosidase A (AGAL). Reduced enzymatic
activity affects the degradation of the complex glycosphingolipid/globotriaosylceramide (also known as GB3 or CD77). Prevaling effect of the impaired GSL catabolism is peripheral neuropathy affecting neurons of autonomic ganglia and Aδ- and C-fibre sensory ganglion cells (see for review Politei et al., 2016). Small fibre neuropathy is characterized by pathological pain, impaired thermosensation and acroparaesthesia, as well as autonomic symptoms of reduced sweating (hyposhidrosis), reduced heart rate variability and orthostatic hypotension (Politei et al., 2016). Cardiac manifestations of the disease include concentric left ventricular hypertrophy leading ultimately to cardiac failure, conduction block and ventricular arrhythmias or tachycardia (Baig et al., 2019), which are mainly accounted for by direct impairments of cardiomyocytes and coronary blood vessels. Recently, an early impairment of cardiac innervation has been demonstrated by SPECT studies showing gradual elimination of the sympathetic nerves innervating the left ventricle in patients affected by Fabry disease (Imbriaco et al., 2017). Similar abnormalities in sensory and autonomic functions have been observed in an animal model of the disease (Hofmann et al., 2018).

### 6.2 Secondary neuropathies: Diabetes

Diabetes mellitus is likely the most frequent metabolic disease that affects peripheral nervous system, especially sensory nerves. Diabetic patients with sensorimotor neuropathy develop clear signs of diffuse autonomic impairment affecting both the visceral sensory system and cardiac autonomic nervous systems (Softeland et al., 2014). Diabetes-associated damage of sensory nerves occurs simultaneously with damage of autonomic nerves. Therefore, in this chapter, we discuss the presentation of cardiovascular autonomic neuropathy (CAN) instead of sensory neuropathy in diabetes mellitus. Cardiovascular autonomic neuropathy damages autonomic nerve fibres causing abnormalities mainly in heart rate and vascular dynamics (Agashe & Petak, 2018).

Cardiovascular autonomic neuropathy is a common complication of diabetes resulting in reduced ejection fraction and diastolic cardiomyopathy (Vouglari, Papadogiannis, & Tentolouris, 2010). It has been shown (Chessa et al., 2002) that a decrease in heart rate variability (HRV), which is an indicator of the reduced influence of parasympathetic efferent activity on the heart, is one of the earliest signs of cardiovascular autonomic neuropathy and is correlated with the duration of hyperglycaemia and the degree of glycemic control in children with insulin dependent diabetes. Type 1 diabetes can cause left ventricular sympathetic dysinnervation with proximal hyperinnervation resulting in severe myocardial perfusion retention and left ventricular dysfunction (Stevens et al., 1998). Hypoglycaemia itself can induce QT interval prolongation, which is one of the major predictor of arrhythmias originated from both sympathto-adrenal activation and a lowered serum potassium level (Lee et al., 2004). Resting tachycardia is not a specific sign of CAN, however increased heart rate enhanced all-causes of mortality in Type 2 diabetic patients, as shown by a recent meta-analysis (Aune et al., 2017). Diagnosis of cardiovascular autonomic neuropathy is still not conclusive, as some diagnostic symptoms are not highly specific for cardiovascular autonomic neuropathy (Spallone, 2019). Cardiovascular signs like tachycardia, QT prolongation and orthostatic hypotension, frequently occur in association with cardiovascular autonomic neuropathy and therefore suggest cardiovascular monitoring in diabetic patents (Spallone et al., 2011). Toronto consensus recommended the use of cardiovascular autonomic reflex tests (Valsalva manoeuvre, heart rate response to deep breathing and standing, and orthostatic hypotension tests) for diagnosis of cardiovascular autonomic neuropathy (Spallone et al., 2011).

Several mechanisms have been revealed from the abundant number of animal models which could be link cardiovascular autonomic neuropathy and worsened cardiac function. However, here we present only some of these mechanisms from the extensive literature. In streptozotocin (STZ)-induced diabetic rats, the left ventricle has a biphasic pattern of sensory innervation in different stages of diabetes (Bakovic et al., 2018). In early diabetes mellitus (between 2 weeks and 2 months after induction) an increase of neurofilament 200 kDa (NF200, a marker for sensory myelinated neurons) and tyrosine-hydroxylase (TH, marker of the sympathetic fibres) protein content could be found in the left ventricular wall and in the interventricular septum compared to control animals. While in the later stages (between 6 and 12 months post-diabetes mellitus induction), the above increases in the density of NF200 and TH immunoreactive fibres have disappeared (Bakovic et al., 2018). In experimental diet and STZ-induced diabetic model of rats, the sensory nerve impairment (validated by tail flick latency test) significantly exaggerated myocardial damages and increased the infarct size and myocyte apoptosis (Li et al., 2017). Using STZ-induced diabetes in Male Sprague–Dawley rats (Xuan et al., 2015), analysis of heart rate variability revealed a relative sympathetic hyperinnervation, which was accompanied with increased ventricular arrhythmogenesis in the diabetic group as compared to the control. However, looking at the immunohistochemistry of choline O-acetyltransferase (ChAT) and L-tyrosine hydroxylase (TH) positive nerve fibres as marker of parasympathetic and sympathetic nerve respectively, short-term diabetes (3 months) resulted in myocardial parasympathetic denervation without significant sympathetic neural damage. By 6 months, sympathetic-parasympathetic imbalance had further developed. This time-dependent neural denervation and heterogeneous innervation might cause relatively sympathetic hyperinnervation, which increases ventricular arrhythmogenesis. Interestingly in the prediabetic state of a diabetic rat model induced by the combination of low-dose STZ and high-fat diet, it was shown that the deterioration of diastolic function and sensory neuropathy occurs earlier than the manifestation of diabetes (Koncsos et al., 2016).

### 6.3 Secondary neuropathies: Autoimmune disorders

Most peripheral neuropathies accompanying autoimmune disorders affect the limbs, however cardiac involvement can also be present (Burakgazi & AlMahameed, 2016).
Systemic lupus erythematosus (SLE) is a complex heterogeneous autoimmune disease characterized by autoantibody production and immune complex deposition followed by damage to target tissues. Chen, Tang, Zhu, and Xu (2016) found in their meta-analysis of 22 studies that patients with SLE develop left ventricular systolic and diastolic dysfunction. Cardiac MR imaging mainly shows vasculitis, myocarditis, and myocardial infarction in patients with SLE (Mavrogeni et al., 2018). Accordingly, many studies reported that SLE patients have much higher cardiovascular risk and higher in-hospital mortality rate after acute myocardial infarction (Ke et al., 2019). SLE may lead to sensory neuropathy, which is limited to the CNS or the optic nerve (Dammacco, 2018), but according to our knowledge there are no available data on sensory neuropathy affecting cardiac nerves in SLE patients. Although there are several animal models, none of them are relevant to the association between sensory neuropathy and the heart.

Rheumatoid arthritis (RA) is a chronic autoimmune disease leading to synovial inflammation and resulting in swelling and pain in and around the joints. Rheumatoid arthritis also affects the cardiovascular system including myocardium. Conduction disturbances and arrhythmias could be signs of cardiac involvement of sensory nerve impairment due to rheumatic diseases (Seferovic et al., 2006). Buleu, Sirbu, Caraba and Dragan, (2019) found that cardiac manifestations of systemic inflammation can occur frequently with different prevalence in rheumatic diseases and it can affect the myocardium, cardiac valves, pericardium, conduction system and arterial vasculature. However, the presence of sensory neuropathy was not tested in any of the above-mentioned studies with rheumatoid arthritis patients. Nevertheless, a recent case report showed a silent myocardial infarction in a rheumatoid arthritis patient with diagnosed cardiac autonomic neuropathy (Unnikrishnan, Jacob, Anthony Diaz, & Lederman, 2016). Animal models for rheumatoid arthritis include induced arthritis models, such as genetically manipulated, the spontaneous arthritis models, such as genetically engineered and experimentally induced models. The autoimmune regulator (Aire) gene-deficient mice develop spontaneous, CD4+ T cell-mediated exocrinopathy, which leads to dry eye that is associated with loss of nerves innervating the cornea and lacrimal gland. Peripheral neuropathies characteristic for Sjögren’s syndrome is tightly linked with the underlying immunopathological mechanism, and Aire−/− mice provide an excellent tool to explore the interplay between Sjögren’s syndrome associated immunopathology and peripheral neuropathy (Chen et al., 2017). However, cardiac effects in the above mouse model have not been investigated yet.

6.4 | Secondary neuropathies: Drug-induced and toxic neuropathies

There are several xenobiotics including drugs, toxins and chemicals, which may cause sensory neuropathy. A detailed list of these compounds is available in a recent review by Karam and Dyck, who distinguished different appearance and manifestation of neuropathies caused by the such compounds (Karam & Dyck, 2015). Since treatment with the specific compound leads to the same deleterious effect on sensory nerves as in humans, detailed descriptions of these models would exceed the scope of the present review.

Anticancer drugs including taxanes, platinum derivatives and vinca alkaloids possess the most abundant literature related to neuropathies, which are predominantly sensory in type. Indeed, morphological studies show degenerative alterations in cutaneous C-fibre innervation following the administration of paclitaxel, vincristine (Siu, Xiao, & Bennett, 2006) and anthracyclines (adriamycin/doxorubicin; Boros et al., 2016) similar to that seen after capsaicin treatment (Dux, Sann, Schemann, & Jancso, 1999). Bortezomib, a proteasome inhibitor used for the treatment of multiple myeloma and thalidomide, an immunomodulatory drug against Mycobacterium subspecies, are also able to evoke severe sensory neuropathy characterized by painful paraesthesia due to the peripheral loss of large myelinated fibres (Karam & Dyck, 2015). In contrast to anthracyclins or taxanes, only the occasional but not severe or significant cardiotoxicity has been shown to be caused by either bortezomib or thalidomide (Reneau et al., 2017).

Among cardiovascular drugs, the cholesterol-lowering statins (simvastatin, pravastatin and fluvastatin) seem to have significant risk factors for the development of primary sensory neuropathy (Jones et al., 2019). However, only a few clinical trials or meta-analysis studies have identified statin-related peripheral neuropathy, which was predominantly of the sensory type (summarized in the review of Jones et al., 2019), and the mechanism is also largely unknown. It is supposed to be associated with energy depletion of neurons due to decreased ubiquinone synthesis. However, their well-known cardioprotective and anti-atherosclerotic effects are far outweigh the
amiodarone, in high dose and over a long duration has a risk of causing sensory and motor deficits in patients (Jones et al., 2019).

There are a couple of antibiotics (nitrofurantoin, linezolid, ethambutol and chloramphenicol) which develop neuropathy during chronic application. However, most of them induce only a slight sensory rather than other types of neuropathies (see for review Karam & Dyck, 2015). The one exception is the group of antiretroviral agents (nucleoside analogue reverse transcriptase inhibitors e.g. zalcitabine and stavudine), which may lead to severe distal sensory neuropathy accompanied by neuropathic pain.

Beyond medical treatments, it is worth mentioning that agriculturally or industrially used compounds, such as organophosphates and vacor (pyrinuron), as well as dimethylaminopropionitrile (Staff & Windebank, 2014), may lead to the development of severe sensory neuropathy (see for review Karam & Dyck, 2015). However, their cardiac effects due to sensory neuropathy are hard to distinguish from their severe systemic actions, for example increased vagal tone due to cholinesterase inhibition (organophosphates) or hyperglycaemic ketoacidosis in case of vacor.

It is well known that chronic ethanol abuse leads to sensory and also motor neuropathy. Specifically, alcohol-related neuropathy presents with a slowly progressive, sensory-dominant symptoms, while thiamine deficiency causes an acutely progressive (<1 month in 56%), primarily motor-dominant features with the loss of ambulation (Koike et al., 2003). Moreover, it has been shown that ethanol intoxication-induced sensory neuropathy alone does not lead to heart failure, only when alcohol abuse was combined with vitamin B1 (thiamine) deficiency (Koike et al., 2003). However, chronic ethanol abuse leads to enhanced cardiac mitochondrial oxidative stress accompanied with myocardial dysfunction, as demonstrated recently by Matyas et al. (2016) using a mouse model of chronic plus binge alcohol feeding-induced ethanol intoxication. Thus, direct cardiac effects of ethanol intoxication show a more pronounced cardiotoxicity than that of indirectly caused by sensory nerve injury.

There are several further toxins including inorganic compounds as thallium, arsenic or lead, as well as biotoxins such as tetrodotoxin, diphtheria or tick paralysis toxin, which may contribute to the development of sensory neuropathy. However, they cause development of complex multi-organ injuries including the heart. Therefore, their discussion would exceed the scope of the present review and are discussed in detail elsewhere (Karam & Dyck, 2015).

It is not known how sensory neuropathy may contribute to the “hidden cardiotoxicity” (a novel concept, i.e. cardiotoxicity seen only in the diseased heart) of some drugs and toxins, including, for example, statins (Ferdinandy et al., 2019).

6.5 | Secondary neuropathies: Vitamin and cofactor deficiencies

Beyond the most common metabolic disorders such as diabetes and the toxic effects of certain drugs, several other factors or diseases can lead to the development of sensory neuropathies. As we previously discussed in ethanol intoxication section, thiamine (vitamin B1) deficiency is also an aetiological factor for sensory (and motor) neuropathy accompanied with cardiovascular complications, based on the results of a study where over 2/3 of the enrolled patients with vitamin B1 deficiency developed signs of heart failure (Koike et al., 2003). The lack of cobalamin (vitamin B12) may cause primary sensory demyelination (Steiner, Kidron, Soffer, Wirguin, & Abramsky, 1988). Puntambekar, Bash, Zak, and Madhavan (2009) reported a case of a patient with vitamin B12 deficiency developing atrial fibrillation and sinus tachycardia due to sensory and autonomic neural dysfunction. However, other publications related to cobalamin deficiency do not refer to any cardiovascular symptoms. It has been shown that isolated vitamin E deficiency may lead to peripheral neuropathy, but it was not accompanied by ECG alterations (Puri, Chaudhry, Tatke, & Prakash, 2005). In contrary, excessive intake of pyridoxin (vitamin B6) also resulted in similar sensory neuropathy both in patients (Gdynia et al., 2008) and in a rat model (Windebank, Low, Blexrud, Schmelzer, & Schaumburg, 1985), but any signs of cardiac dysfunctions were not measured.

6.6 | Secondary neuropathies: Others

Infections by human immunodeficiency virus (Karpul, McIntyre, van Schaik, Breen, & Heckmann, 2019), hepatitis C (Yoon et al., 2011) or Zika virus (Medina & Medina-Montoya, 2017), as well as alteration of hormonal status such as hypothyroidism (Eslamian et al., 2011) have been shown to lead to sensory neuropathy. Guillain–Barré syndrome is a rare disease when the immune system starts to attack the nervous system primarily causing acute inflammatory demyelinating polyradiculoneuropathy (Burakgazi & AlMaheameed, 2016). The autonomic and cardiovascular involvement in Guillain–Barré syndrome involve mainly the autonomic fibres (Burakgazi & AlMaheameed, 2016). However, in all the above-mentioned conditions, the aetiologial role of sensory dysfunction in the cardiovascular complications is not obvious; cardiac pathology develops directly in response to the primary disease (i.e. infections or hormonal disorders).

7 | SENSORY NEUROPATHY AND ITS PRECLINICAL MODELS

Sensory neuropathy denotes diseases of the sensory nerves in which either the axon or the myelin-forming cells are dysfunctional due to metabolic, toxic, infectious or genetic causes, which results in several clinical symptoms like hyperalgesia, allodynia or the opposite, reduced ability to sense pain or extreme temperatures and paraesthesias (Ochoa, 1995). There are plenty of pathologies leading to sensory neuropathies (see more details on animal models above), although isolated sensory neuropathy can be achieved experimentally by the systemic application of capsaicin or its ultrapotent analogue, resiniferatoxin.
Neurochemical and histochemical studies have demonstrated a remarkable reductions in substance P and CGRP levels in sensory nerves (Gamse et al., 1981), including cardiac nerves (Ferdinandy et al., 1997), after systemic capsaicin treatment, also referred to as capsaicin desensitization or selective sensory chemodenervation (Dux et al., 1999). This is a unique and selective experimental tool that is used to mimic sensory neuropathies induced by metabolic disorders or drug treatments allows the investigation of the role of peptidergic capsaicin-sensitive sensory nerves in a variety of pathophysiological mechanisms.

Resiniferatoxin is an ultrapotent analogue of capsaicin, which also selectively acts on primary sensory neurons resulting in ultrastructural alterations and CGRP depletion. Resiniferatoxin does not change heart rate or BP nor does it provoke the pulmonary chemoreflex in the rat, the latter is the main limiting factor in capsaicin treatment (Szolcsányi, Szallas, Szallas, Joo, & Blumberg, 1990). This suggests a further advantage in using resiniferatoxin to investigate capsaicin-sensitive neural pathways (Szolcsanyi et al., 1990). In isolated rat cardiac mitochondria, resiniferatoxin caused concentration-dependent decrease in oxygen consumption and lowered mitochondrial membrane potential (Athanasiou et al., 2007), since TRPV1 channels are located in intracellular and mitochondrial membranes as well.

Resiniferatoxin application has beneficial effects on cardiac and autonomic dysfunction in rats with myocardial infarction-induced chronic heart failure. Epidural application of resiniferatoxin in rats 9–11 weeks after the myocardial ischaemia interrupts already activated cardiac sympathetic afferents, thereby reducing a major source of sympatho-excitation in chronic heart failure. This experimental result shows the importance and therapeutic potential of targeted desensitization of cardiac sympathetic afferent reflex in ventricular remodelling after myocardial infarction (Wang, Wang, Cornish, Rozanski, & Zucker, 2014). Furthermore, epidural resiniferatoxin application lowered diastolic BP both at daytime and night-time with less effect on systolic BP in chronic heart failure rats compared to the sham group. Cardiac sympathetic afferent reflex activation physiologically causes significant increase in cardiac contractility and output (Wang, Rozanski, & Zucker, 2017). In the rat model of transverse aortic constriction-induced cardiac remodelling resiniferatoxin pre-treatment improved haemodynamic data (reduced left ventricular end-diastolic pressure) and also prevented cardiac hypertrophy, fibrosis and apoptosis. Focal chemo-ablation of TRPV1+ neurons in the spinal cord protects the heart from pressure overload-induced cardiac remodelling and cardiac dysfunction, which could be a promising novel therapeutic treatment against cardiac hypertrophy and diastolic dysfunction (Wang, Wu, et al., 2019).

8 | SIMULTANEOUS THERAPEUTIC OPTIONS FOR THE ISCHAEMIC HEART IN SENSORY NEUROPATHY

There is no available drug treatment for indications of sensory neuropathy approved by the Federal Drug Agency or the European Medicines Agency. In most cases, the treatment of sensory neuropathy consists of the symptomatic pharmacological treatment of neuropathic pain related to diabetes- or chemotherapy-induced neuropathy. Gwathmey and Pearson (2019) summarized their findings on the above therapies and classified them in three levels (A to C, where A is the most preferable) according to the strength of evidence for efficacy. According to the above-mentioned review, at Level A, the treatment of neuropathic pain can be treated with the following drugs, gabapentin, pregabalin, venlafaxine, duloxetine, tricyclic antidepressants (e.g. amitriptyline), tramadol and oxycodone, at Level B valproate, dextromethorphan, capsaicin and botulinum toxin should be used, while at Level C carbamazepine. Since there is no causal treatment for sensory neuropathy, there is an utmost need for novel therapeutic targets focusing on preservation of physiological functions of nerves/neurons and cardiac myocytes simultaneously. In Clinicaltrials.gov database, 56 studies can be found by the term “sensory neuropathy.” In 20 of these studies, the study protocol includes pharmacological approaches to improve the primary disease or to alleviate pain symptoms, however none of them relates to cardioprotection.

One of the most promising novel drug candidates in experimental phase is BGP-15 that could improve hereditary sensory and autonomic neuropathy Type III (HSAN III, also called FD). FD is a genetic disorder caused by a single base substitution in the IKBKAP gene resulting in disruption development of the peripheral nervous system, which also affects sensory nerves. This condition can have fatal consequences resulting from functional and electrophysiological instability, respiratory dysfunction and/or sudden death during sleep (Norcliffe-Kaufmann, Slagenhaupt, & Kaufmann, 2017). Ohlen et al. (2017) demonstrated by using an Ikbkap/Elp1 conditional-knockout mouse model that daily injections of BGP-15 (O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime), a cardioprotective compound developed by a Hungarian biotech company in late 1990s, significantly improved cardiac innervation and prevented the death of Ikbkap−/− neurons (Table 2). BGP-15 was basically developed against PARP as an insulin sensitizer drug, but it has been shown that it protects isolated rat hearts against ischaemia/reperfusion injury (Szabados, Literati-Nagy, Farkas, & Sumegi, 2000). Recently, BGP-15 has been shown to prevent the impairment of sensory nerves conduction velocity in cisplatin- or taxol-induced peripheral neuropathy in rats (Bárdos et al., 2003). More recently, BGP-15 was applied against diabetic cardiomyopathy in a spontaneous diabetic Goto-Kakizaki rat model (Bombicz et al., 2019). The BGP-15-treatment considerably enhanced diastolic function and improved Tei-index in Goto-Kakizaki rats, by affecting the SERCA/phospholamban pathway (Bombicz et al., 2019). Beneficial effects of BGP-15 have been shown in models of diabetes, muscular dystrophy, HSAN and also in heart failure, where it has affected chaperones, contractile and mitochondrial proteins, as well as SERCA (Gehrig et al., 2012; Ohlen et al., 2017; Sapra et al., 2014).

To find efficacious treatment for diabetes mellitus-associated sensory neuropathy is critical since the incidence of diabetes and thereby the appearance of sensory neuropathy is rapidly increasing
### TABLE 2  Novel and promising therapeutic approaches to improve sensory neuropathy and to decrease infarct size/preserve cardiac function

| Drug/agent                                      | Aetiology                        | Therapeutic target                                      | Achieved improvement                                                                 | References                                   |
|------------------------------------------------|----------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------|
| **Therapies approved by FDA/EMA**               |                                  |                                                        |                                                                                      |                                             |
| α-Lipoic acid                                   | Diabetes-associated CAN          | Antioxidant therapy to decrease diabetic oxidative stress | Improvement of diabetes-induced CAN symptoms; reduction in myocardial infarct size    | Deng et al., 2013; Ziegler et al., 1997    |
| α-Tocopherol                                    | Diabetes-associated CAN          | Antioxidant therapy to decrease diabetic oxidative stress | Improvement of diabetes-induced CAN symptoms; decreased infarct size and improved left ventricular function | Wallert et al., 2019; Ziegler et al., 1997 |
| **Therapies under preclinical or clinical investigation** |                                  |                                                        |                                                                                      |                                             |
| BGP-15                                          | HSAN Type III (Familial dysautonomia) | IKBKAP gene                                         | Protects isolated rat hearts against ischaemia/reperfusion injury; significantly improves cardiac innervation, prevents the death of Ikbkap−/− neurons | Bombicz et al., 2019; Ohlen et al., 2017; Szabados et al., 2000 |
| Aldose reductase inhibitors (ranirestat, zopolrestat, and epalrestat) | Diabetes-associated CAN | Aldose reductase, blocks polyol pathway | Reduce myocardial infarct size in Type 1 diabetes; improvement of sensory nerve conduction velocity in both Type 1 or Type 2 diabetic patients | Annapurna et al., 2008; Sekiguchi et al., 2019 |
| PDE5 inhibitors (sildenafil, vardenafil, and tadanafil) | Type 2 diabetes-induced sensory neuropathy | PDE type 5 | Reduction in infarct size in both normal and Type 2 diabetic rodents; improve diabetes-induced HFpEF symptoms | Varma et al., 2012; Wang et al., 2016, Matyas et al., 2017 |
| Nerve growth factor (NGF)                       | Type 1 or Type 2 diabetes        | Facilitates TRPV1 development                          | Attenuated reperfusion injury of diabetic rat hearts; Adenovirus-mediated NGF gene delivery prevented sensory neuropathy in bone marrow and restored blood flow in limb ischaemia | Dang et al., 2019; Zheng et al., 2015 |

CAN; cardiovascular autonomic neuropathy.
worldwide. As we discussed above, cardiovascular autonomic neuropathy is a frequent complication of diabetes. It was shown that there is a prognostic value of cardiovascular autonomic neuropathy for cardiovascular mortality and morbidity in both Type 1 and Type 2 diabetes (Spallone, 2019). Besides the association with both fatal- and non-fatal cardiovascular events, cardiovascular autonomic neuropathy also showed strong correlation with glycaemic control (Pop-Busui et al., 2017). Prevention and existing treatment of cardiovascular autonomic neuropathy include lifestyle modifications and strict control of blood glucose level (involving oral antidiabetic drugs or insulin therapy if needed). However, the pathogenesis-based pharmacological treatment consists of antioxidant therapy such as α-lipoic acid and vitamin E (Table 2; Ziegler et al., 1997). α-Lipoic acid has been recently shown to reduce myocardial infarct size when administrated 30 min before coronary occlusion in rats (Deng et al., 2013). Most recently, α-tocopherol, the strongest antioxidant form of vitamin E, applied 2 hr prior to 60-min coronary occlusion, immediately after reperfusion and twice per day for three consecutive days in mice, has been shown to decrease infarct size and improve left ventricular function 4 weeks after the development of acute myocardial infarction (Wallert et al., 2019). As an alternative option for improving sensory function in diabetic patients suffering from cardiovascular autonomic neuropathy is the inhibitors of aldose reductase (Table 2; e.g. ranirestat, zopolrestat and epalrestat). Ranirestat and zopolrestat are already tested in clinical phases and have been shown to improve sensory nerve conduction velocity in both Type 1 and Type 2 diabetic patients (Sekiguchi et al., 2019) and to stabilize or partially reverse left ventricular abnormalities in cardiovascular autonomic neuropathy patients (Fisher & Tahrani, 2017). Moreover, non-selective inhibition of aldose reductase by suldinac has been shown to reduce myocardial infarct size in normal and also in STZ-induced diabetic rats (Annapurna, Challa, Prakash, & Viswanath, 2008).

Recently, a novel cardiovascular and anti-diabetic/anti-neuropathic indication for phosphodiesterase type 5 (PDE5) inhibitors (e.g. sildenafil, tadalafil and vardenafil) have been intensively studied. PDE5 selectively hydrolysates the second messenger cGMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP-dependent pathway plays a crucial role in various cardiovascular diseases such as erectile dysfunction and pulmonary hypertension (Tsai & Kass, 2009). Tadalafil has previously been shown to reduce infarct size in both normal and Type 2 diabetic rats and mice (Table 2; reviewed in Das, Durrant, Salloum, Xi, & Kukreja, 2015). Furthermore, it has been shown that tadalafil improves sensory nerve conduction velocity in Type 2 diabetic db/db mice (Wang et al., 2016). Long-term administration of vardenafil led to effective prevention of developing HFpEF characterized by increased myocardial stiffness and worsened diastolic function in Type 2 diabetic Zucker diabetic fatty rats. In the same study, vardenafil treatment also reduced the pathophysiological features of diabetes-associated cardiomyopathy and restored the activity of cGMP–PKG axis by increasing myocardial and plasma cGMP levels (Matyas et al., 2017). Thus, PDE5 inhibition may simultaneously reduce myocardial infarct size, achieve improvement in Type 2 diabetes, one of the major causes of sensory neuropathy and recovers myocardium from HFpEF. However, the proportion of diabetes-induced sensory neuropathy in the development of diabetic HFpEF still remains the subject of further investigations.

9 | CONCLUSIONS AND FUTURE PERSPECTIVES

Abundant data from literature demonstrate that sensory nerves play pivotal roles in the physiological and pathological of the heart. Despite, in the last decades, research starting to focus on the role of cardiac innervation in cardiac pathologies and cardioprotection, little is still known on the mechanism and the effect of sensory neuropathy on cardiovascular morbidities, especially ischaemic heart disease and cardioprotection. Nevertheless, several promising therapeutic approaches have emerged recently which may have beneficial actions on myocardial ischaemic injury and simultaneously improve the symptoms of sensory neuropathy of different aetiologies.

9.1 | Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked in corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander et al., 2019).

ACKNOWLEDGEMENTS

This research was funded by the National Research, Development and Innovation Office of Hungary, Project IDs: GINOP-2.3.2-15-2016-00040 acronym: "MYOTeam" and NVKP 16-1-2016-0017 financed under the NVKetP_16 funding scheme. The research was also financed by the Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of the therapeutic development thematic programme of the Semmelweis University.

CONFLICT OF INTEREST

P.F. is the founder and CEO of Pharmahungary, a group of R&D companies.

ORCID

Péter Bencsik https://orcid.org/0000-0003-1936-6232
Kamilla Gámori https://orcid.org/0000-0001-9793-3138

REFERENCES

Adams, D., Koike, H., Slama, M., & Coelho, T. (2019). Hereditary transthyretin amyloidosis: A model of medical progress for a fatal disease. Nature Reviews. Neurology, 15, 387–404. https://doi.org/10.1038/s41582-019-0210-4
Asquith, D. L., Miller, A. M., McInnes, I. B., & Liew, F. Y. (2009). Animal
Aune, D., Sen, A., o’Hartaigh, B., Janszky, I., Romundstad, P. R.,
Andrei, S. R., Sinharoy, P., Bratz, I. N., & Damron, D. S. (2016). TRPA1 is
Bencsik, P., Kupai, K., Giricz, Z., Babos, G., Móricz, K., Jaszlits, L., Rabloczky, G., Tory, K., Rácz, I.,
Bombicz, M., Prikzs, D., Gezstelyi, R., Kiss, R., Hollos, L., Varga, B., 
Juhasz, B. (2019). The drug candidate BCG-15 delays the onset of dia-
Bárdos, G., Móricz, K., Jaszlits, L., Rabloczky, G., Tory, K., Rácz, I.,
Ferdinandy, P. (2019). Sensory neuropathy affects cardiac miRNA
Chessa, M., Butera, G., Lanza, G. A., Bossone, E., Delogu, A., De Rosa, G., 
Choudhary, N., Bhatt, L. K., & Prabhavalkar, K. S. (2018). Experimental ani-
Boros, K., Jancso, G., Dux, M., Fekecs, Z., Bencsik, P., Oszlacs, O., 
Sántha, P. (2016). Multiple impairments of cutaneous nociceptor func-
tion induced by cardiotoxic doses of Adriamycin in the rat. Naunyn-
Schmiedeberg’s Archives of Pharmacology, 389, 1009–1020. https://doi.
or/10.1007/s00210-016-1267-x
Boyette-Davis, J., Xin, W., Zhang, H., & Dougherty, P. M. (2011). Intra-
epidermal nerve fiber loss corresponds to the development of taxol-
induced hyperalgesia and can be prevented by treatment with min-
ocycline. Pain, 152(2), 308–313.
Buleu, F., Sirbu, E., Caraba, A., & Dragan, S. (2019). Heart involvement in
inflammatory rheumatic diseases: A systematic literature review. 
Medicina (Kaunas, Lithuania), 55, 249. https://doi.org/10.3390/medicina55060249
Burakgazi, A. Z., & AlMahameed, S. (2016). Cardiac involvement in
peripheral neuropathies. Journal of Clinical Neuromuscular Disease, 17, 
120–128. https://doi.org/10.1007/CND.0000000000001016
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., 
Levine, J. D., & Julius, D. (1997). The capsaicin receptor: A heat-
activated ion channel in the pain pathway. Nature, 389, 816–824. 
https://doi.org/10.1038/39807
Chen, F. Y., Lee, A., Ge, S., Nathan, S., Knox, S. M., & McNamara, N. A. (2017). Aire-deficient mice provide a model of corneal and lacrimal gland neuropathy in Sjögren’s syndrome. PLoS ONE, 12, e0184916. 
https://doi.org/10.1371/journal.pone.0184916
Chen, J., Tang, Y., Zhu, M., & Xu, A. (2016). Heart involvement in systemic lupus erythematosus: A systemic review and meta-analysis. Clinical 
Rheumatology, 35, 2437–2448. https://doi.org/10.1007/s10067-016-3373-z
Chen, Y. T., Hims, M. M., Shetty, R. S., Mull, J., Liu, L., Levyne, M., 
& Slaugenhaupt, S. A. (2009). Loss of mouse Ikbkap, a subunit of elon-
gator, leads to transcriptional deficits and embryonic lethality that can 
be rescued by human IKBKAP. Molecular and Cellular Biology, 29, 
736–744. https://doi.org/10.1128/MCB.01313-08
Chessa, M., Butera, G., Lanza, G. A., Bossone, E., Delogu, A., De Rosa, G., 
... Carminati, M. (2002). Role of heart rate variability in the early diag-
nosis of diabetic autonomic neuropathy in children. Herz, 27, 
785–790. https://doi.org/10.1007/s00059-002-2340-4
Choudhary, N., Bhatt, L. K., & Prabhavalkar, K. S. (2018). Experimental ani-
mal models for rheumatoid arthritis. Immunopharmacology and Immu-
notoxicology, 40, 193–200. https://doi.org/10.1080/08929377.2018. 
1434793
Conklin, D. J., Guo, Y., Nystoriak, M. A., Jagatheesan, G., Obal, D., 
Kilfoil, P. J., et al. (2017). Aire-deficient mice provide a model of corneal and lacrimal gland neuropathy in Sjögren’s syndrome. PLoS ONE, 12, e0184916. 
https://doi.org/10.1371/journal.pone.0184916
Corréard, S., Plassais, J., Lagoutte, L., Botherel, N., Thibaud, J. L., Heden, B., 
... André, (2019). Canine neuropathies: Powerful spontaneous models 
for human hereditary sensory neuropathies. Human Genetics, 138, 
455–466. https://doi.org/10.1007/s00439-019-02003-x
Dammacco, R. (2018). Systemic lupus erythematosus and ocular involve-
ment: An overview. Clinical and Experimental Medicine, 18, 135–149. 
https://doi.org/10.1007/s12328-017-0479-9
Dang, Z., Avolio, E., Albertario, A., Sala-Newby, G. B., Thomas, A. C., 
Wang, N., ... Molecules, 24. https://doi.org/10.3390/ 
molecules24030586
Deng, C., Sun, Z., Tong, G., Yi, W., Ma, L., Zhao, B., ... Yi, D. (2013). «Lipoic acid reduces infarct size and preserves cardiac function in rat myocardial ischemia/reperfusion injury through activation of PI3K/Akt/Nrf2 pathway. PLoS ONE, 8, e58371. https://doi.org/10.1371/journal.pone.0058371

Dietrich, P., Alli, S., Shanmugasundaram, R., & Dragatis, I. (2012). IKAP expression levels modulate disease severity in a mouse model of familial dysautonomia. Human Molecular Genetics, 21, 5078–5090. https://doi.org/10.1093/hmg/ddz354

Durr, A., Cossee, M., Agid, Y., Campuzano, V., Mignard, C., Penet, C., ... Koenig, M. (1996). Clinical and genetic abnormalities in patients with Friedreich's ataxia. The New England Journal of Medicine, 335, 1169–1175. https://doi.org/10.1056/NEJM199610173351601

Dux, M., Sann, H., Schemann, M., & Jancso, G. (1999). Changes in fibre preconditioning, postconditioning, and remote conditioning. With ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Trends in Pharmacological Sciences, 20, 323–328. https://doi.org/10.1016/S0165-6147(98)01212-7

Elliott, M. D., Heitner, J. F., Kim, H., Wu, E., Parker, M. A., Lee, D. C., ... Koenig, M. (1996). Clinical and genetic abnormalities in patients with Friedreich's ataxia. The New England Journal of Medicine, 335, 1169–1175. https://doi.org/10.1056/NEJM199610173351601

Ferdinandy, P., Szilvassy, Z., & Baxter, G. F. (1998). Adaptation to myocardial ischemia/reperfusion injury and ischemic stress adaptation. Role of nitric oxide and calcitonin gene-related peptide. Neurogenic inflammation in health and disease (pp. 267–288). Amsterdam: Elsevier.

Fisher, V. L., & Tahiani, A. A. (2017). Cardiac autonomic neuropathy in patients with diabetes mellitus: Current perspectives. Diabetes, Metabolic Syndrome and Obesity, 10, 419–434. https://doi.org/10.2147/DMSO.S129797

Franco-Cereceda, A., & Lundberg, J. M. (1988). Actions of calcitonin gene-related peptide and tachykinins in relation to the contractile effects of capsaicin in the guinea-pig and rat heart in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology, 337, 649–655. https://doi.org/10.1007/BF00175791

Gamse, R., Lackner, D., Gamse, G., & Leeman, S. E. (1981). Effect of capsaicin pretreatment on capsaicin-evoked release of immunoreactive somatostatin and substance P from primary sensory neurons. Naunyn-Schmiedeberg's Archives of Pharmacology, 316, 38–41. https://doi.org/10.1007/BF00507224

Gdy尼亚, H. J., Muller, T., Sperfeld, A. D., Kuhnlein, P., Otto, M., Kassubek, J., & Ludolph, A. C. (2008). Severe sensorimotor neuropathy after intake of highest dosages of vitamin B6. Neuro muscular Disorders, 18, 156–158. https://doi.org/10.1016/j.nmd.2007.09.009

Gehrig, S. M., van der Poel, C., Sayer, T. A., Schertzer, J. D., Henstridge, D. C., Church, J. E., ... Lynch, G. S. (2012). Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature, 484, 394–398. https://doi.org/10.1038/nature10980

Grise, K. N., Olver, T. D., McDonald, M. W., Dey, A., Jiang, M., Lacefield, J. C., ... Melling, C. W. (2016). High intensity aerobic exercise training improves deficits of cardiovascular autonomic function in a rat model of type 1 diabetes mellitus with moderate hyperglycemia. Journal of Diabetes Research, 2016, 8164518.

Goldstein, D. S., Eldadah, B., Sharabi, Y., & Axelrod, F. B. (2008). Cardiac sympathetic hypo-innervation in familial dysautonomia. Clinical Autonomic Research, 18, 115–119. https://doi.org/10.1016/s1028-008-0464-1

Gwathmey, K. G., & Pearson, K. T. (2019). Diagnosis and management of sensory polyneuropathy. BMJ, 365, 11108.

Harding, S. D., Sharan, J. L., Facenda, E., Southan, C., Pawson, A. J., Ireland, S., ... NC-IUPHAR. (2018). The IUPHAR/BPS Guide to pharmacology in 2018: Updates and expansion to encompass the new guide to immunopharmacology. Nucleic Acids Research, 46(D1), D1091–D1106. https://doi.org/10.1093/nar/gkx1121

Harmer, A. J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J. R., ... Said, S. I. (2012). Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. British Journal of Pharmacology, 166, 4–17. https://doi.org/10.1111/j.1476-5381.2012.01871.x

Hausenloy, D. J., Botker, H. E., Ferdinand, P., Heusch, G., Ng, G. A., Redington, A., & Garcia-Dorado, D. (2019). Cardiac innervation in acute myocardial ischaemia/reperfusion injury and cardioprotection. Cardiovascular Research, 115, 1167–1177. https://doi.org/10.1093/cvr/cvz053

Hausenloy, D. J., Garcia-Dorado, D., Botker, H. E., Davidson, S. M., Downey, J., Engel, F. B., ... Ovize, M. (2017). Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 113, 564–585. https://doi.org/10.1093/cvr/cvx049

Hims, M. M., Shetty, R. S., Pickel, J., Mull, J., Leyne, M., Liu, L., ... Slaugenhaupt, S. A. (2007). A humanized iKBKAP transgenic mouse models a tissue-specific human splicing defect. Genomics, 90, 389–396. https://doi.org/10.1016/j.ygeno.2007.05.012

Hofmann, L., Hose, D., Griesshammer, A., Blum, R., Doring, F., Dib-Hajj, S., ... Uçeyler, N. (2018). Characterization of small fiber pathology in a mouse model of Fabry disease. eLife, 7, https://doi.org/10.7554/eLife.39300

Holzer, P. (1988). Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience, 24, 739–768. https://doi.org/10.1016/0306-4522(88)90064-4

Huxley, C., Passage, E., Robertson, A. M., Youl, B., Huston, S., Manson, A., ... Fontes, M. (1998). Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Human Molecular Genetics, 7(3), 449–458.

Ieda, M., & Fukuda, K. (2009). Cardiac innervation and sudden cardiac death. Current Cardioiology Reviews, 5, 289–295. https://doi.org/10.2174/157340309789317904

Imbriaco, M., Pellegrino, T., Piscopo, V., Petretta, M., Ponsiglione, A., Nappi, C., ... Cuocolo, A. (2017). Cardiac sympathetic neuronal damage
precedes myocardial fibrosis in patients with Anderson-Fabry disease. *European Journal of Nuclear Medicine and Molecular Imaging*, 44, 2266–2273. https://doi.org/10.1007/s00259-017-3778-1

Inoue, H., Kinoshita, K., Sugiyama, M., Funachi, M., Hanagama, M., & Nata, M. (2008). Sudden death from ischaemic heart disease in a female patient with Sjögren syndrome: A case report. *Medicine, Science, and the Law*, 48, 261–265. https://doi.org/10.1258/rsmssl.48.3.261

Inoue, K., Dewar, K., Katsanis, N., Reiter, L. T., Lander, E. S., Devon, K. L., ... Birren, B. (2001). The 1.4-Mb CMT1A duplication/HNPP deletion genomic region reveals unique genome architectural features and provides insights into the recent evolution of new genes. *Genome Research*, 11, 1018–1033. https://doi.org/10.1101/gr.180401

Jancso, G., Kiraly, E., & Jancso-Gabor, A. (1977). Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. *Nature*, 270, 741–743. https://doi.org/10.1038/270741a0

Jancso, G., Kiraly, E., Joo, F., Such, G., & Nagy, A. (1985). Selective degeneration by capsaicin of a subpopulation of primary sensory neurons in the adult rat. *Neuroscience Letters*, 59, 209–214. https://doi.org/10.1016/0304-3940(85)90201-0

Jancso, G., Kiraly, E., Such, G., Joo, F., & Nagy, A. (1987). Neurotoxic effect of capsaicin in mammals. *Acta Physiologica Hungarica*, 69, 295–313.

Jancso, G., & Knylvah, E. (1975). Functional linkage between nociception and fluoride-resistant acid phosphatase activity in the Rolando substance. *Neurobiology*, 5, 42–43.

Jancso, G., & Such, G. (1983). Effects of capsaicin applied perineurally to the vagus nerve on cardiovascular and respiratory functions in the cat. *The Journal of Physiology*, 341, 359–370. https://doi.org/10.1113/jphysiol.1983.sp014810

Jancsó, G. F.-C. A. (1998). Aggravation of myocardial infarction in the porcine heart by capsaicin-induced depletion of calcitonin gene-related peptide (CGRP). *Journal of Cardiovascular Pharmacology*, 32, 500–504. https://doi.org/10.1097/00002416-199809000-00023

Jones, M. R., Urits, I., Wolf, J., Corrigan, D., Colburn, L., Peterson, E., ... Viswanath, O. (2019). Drug-induced peripheral neuropathy: An exploratory study. *Annals of Neurology*, 85, 598–613. https://doi.org/10.1002/ana.10550

Konczos, G., Varga, Z. V., Baranyai, T., Boengler, K., Rohrbach, S., Li, L., ... Ferdinandy, P. (2016). Diastolic dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress. *American Journal of Physiology. Heart and Circulatory Physiology*, 311, H927–H943. https://doi.org/10.1152/ajpheart.00049.2016

Kovacs, L., Paprika, D., Takacs, R., Kardos, A., Varkonyi, T. T., Lengyel, C., ... Pokorny, G. (2004). Cardiovascular autonomic dysfunction in primary Sjögren’s syndrome. *Rheumatology (Oxford)*, 43, 95–99. https://doi.org/10.1093/rheumatology/keg468

Lai, H. J., Huang, K. C., Liang, Y. C., Chien, K. L., Lee, M. J. M., Hsieh, S. T., ... Yang, C. C. (2019). Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser. *Journal of the Formosan Medical Association*. https://doi.org/10.1016/j.jfma.2019.08.027

Lam, C. S., Donal, E., Kraigher-Krainer, E., & Vasan, R. S. (2011). Epidemiology and clinical course of heart failure with preserved ejection fraction. *European Journal of Heart Failure*, 13, 18–28. https://doi.org/10.1093/eurjhf/hfq121

Lee, S. P., Yeoh, L., Harris, N. D., Davies, C. M., Robinson, R. T., Leathard, A., ... Keller, S. R. (2004). Influence of autonomic neuropathy on QTc interval lengthening during hypoglycaemia in type 1 diabetes. *Diabetes*, 53, 1535–1542. https://doi.org/10.2337/diabetes.53.6.1535

Lehmonen, L., Kaasalainen, T., Atula, S., Mustonen, T., & Holmstrom, M. (2019). Myocardial tissue characterization in patients with hereditary gelsolin (AGel) amyloidosis using novel cardiovascular magnetic resonance techniques. *The International Journal of Cardiovascular Imaging*, 35, 351–358. https://doi.org/10.1007/s10554-019-01570-4

Li, T. P., Guo, Z., Liu, C. J., Sun, T., Chen, L., & Zhao, X. (2017). Association of down-regulation of calcitonin gene-related peptide and substance P with increase of myocardial vulnerability in diabetic neuropathic rats. *Pepptides*, 96, 1–7. https://doi.org/10.1016/j.peptides.2017.08.007

Li, Y. J., & Peng, J. (2002). The cardioprotection of calcitonin gene-related peptide-mediated preconditioning. *European Journal of Pharmacology*, 442, 173–177. https://doi.org/10.1016/s0014-2999(02)01539-8

Li, Y. J., Xiao, Z. S., Peng, C. F., & Deng, H. W. (1996). Calcitonin gene-related peptide-induced preconditioning protects against ischemia-reperfusion injury in isolated rat hearts. *European Journal of Pharmacology*, 311, 163–167. https://doi.org/10.1016/0014-2999(96)00426-8

Liem, D. A., Verdouw, P. D., Ploeg, H., Kazim, S., & Duncker, D. J. (2002). Sites of action of adenosine in interorgan preconditioning of the heart. *American Journal of Physiology. Heart and Circulatory Physiology*, 283, H29–H37. https://doi.org/10.1152/ajpheart.01031.2001

Lu, Y., Pipiani, H., McCallister, S. L., Hurt, C. M., & Gross, E. R. (2016). Transient receptor potential ankyrin 1 activation within the cardiac myocyte limits ischemia-reperfusion injury in rodents. *Anesthesiology*, 125, 1171–1180. https://doi.org/10.1097/ALN.0000000000001377

Lynch-Godrei, A., De Repentigny, Y., Gagnon, S., Trung, M. T., & Kothary, R. (2018). Dystonin-A3 upregulation is responsible for maintenance of tubulin acetylation in a less severe dystonia musculorum mouse model for hereditary sensory and autonomic neuropathy type VI. *Human Molecular Genetics*, 27, 3598–3611. https://doi.org/10.1093/hmg/ddy250
Pop-Busui, R., Braffett, B. H., Zinman, B., Martin, C., White, N. H., Herman, W. H., ... Serebrinsky, G., Pironti, G., Bersellini-Farinotti, A., Agalave, N. M., Sandor, K., Fernandez-Bencksik, E., Matyas, C., Varga, Z. V., Mukhopadhyay, P., Paloczi, J., Erdelyi, K., ... A randomized double-blind placebo-controlled study in Japan. Journal of Diabetes Investigation, 10, 466–474. https://doi.org/10.1111/jdi.12890

Sereda, M., Griffiths, I., Puhlhofer, A., Stewart, H., Rossner, M. J., Zimmerman, F., ... Nave, K. A. (1996). A transgenic rat model of Charcot-Marie-Tooth disease. Neuron, 16(5), 1049–1060.
Yoon, M. S., Obermann, M., Dockweiler, C., Assert, R., Canbay, A., Haag, S., ... Katsarava, Z. (2011). Sensory neuropathy in patients with cryoglobulin negative hepatitis-C infection. *Journal of Neurology, 258*, 80–88. https://doi.org/10.1007/s00415-010-5686-1

Yoshida, M., Kataoka, N., Miyauchi, K., Ohe, K., Iida, K., Yoshida, S., ... Hagiwara, M. (2015). Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia. *Proceedings of the National Academy of Sciences of the United States of America, 112*, 2764–2769. https://doi.org/10.1073/pnas.1415525112

Zhang, R. L., Guo, Z., Wang, L. L., & Wu, J. (2012). Degeneration of capsaicin sensitive sensory nerves enhances myocardial injury in acute myocardial infarction in rats. *International Journal of Cardiology, 160*, 41–47. https://doi.org/10.1016/j.ijcard.2011.03.025

Zheng, L. R., Zhang, Y. Y., Han, J., Sun, Z. W., Zhou, S. X., Zhao, W. T., & Wang, L. H. (2015). Nerve growth factor rescues diabetic mice heart after ischemia/reperfusion injury via up-regulation of the TRPV1 receptor. *Journal of Diabetes and its Complications, 29*, 323–328. https://doi.org/10.1016/j.jdiacomp.2015.01.006

Zhong, B., & Wang, D. H. (2008). N-oleoyldopamine, a novel endogenous capsaicin-like lipid, protects the heart against ischemia-reperfusion injury via activation of TRPV1. *American Journal of Physiology. Heart and Circulatory Physiology, 295*, H728–H735. https://doi.org/10.1152/ajpheart.00220.2008

Zhou, M., Liu, Y., He, Y., Xie, K., Quan, D., Tang, Y., ... Huang, C. (2019). Selective chemical ablation of transient receptor potential vanilloid 1 expressing neurons in the left stellate ganglion protects against ischemia-induced ventricular arrhythmias in dogs. *Biomedicine & Pharmacotherapy, 120*, 109500. https://doi.org/10.1016/j.biopha.2019.109500

Ziegler, D., Schatz, H., Conrad, F., Gries, F. A., Ulrich, H., & Reichel, G. (1997). Effects of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). *Deutsche Kardiale Autonome Neuropathie. Diabetes Care, 20*, 369–373. https://doi.org/10.2337/diacare.20.3.369

Zipse, M. M., & Aleong, R. G. (2016). Acquired pulmonary vein isolation in a patient with Friedreich ataxia. *Cardiac Electrophysiology Clinics, 8*, 151–153. https://doi.org/10.1016/j.ccep.2015.10.016

Zvara, A., Bencsik, P., Fodor, G., Csont, T., Hackler, L. Jr., Dux, M., ... Ferdinandy, P. (2006). Capsaicin-sensitive sensory neurons regulate myocardial function and gene expression pattern of rat hearts: A DNA microarray study. *The FASEB Journal, 20*, 160–162. https://doi.org/10.1096/fj.05-4060fje

How to cite this article: Bencsik P, Gömöri K, Szabados T, et al. Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options. *Br J Pharmacol*. 2020;1–21. https://doi.org/10.1111/bph.15021